Recurrent Pleural Effusion in an Elderly Patient With Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy.

Document Type

Article

Publication Date

6-12-2025

Publication Title

Cureus

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder treated with tyrosine kinase inhibitors (TKIs). While TKIs are effective in treating CML, their adverse effects can impact patient management. We present a case of an 83-year-old female diagnosed with CML in August 2024, initially treated with dasatinib but discontinued due to gastrointestinal toxicity. She was later started on imatinib in October 2024. One month later, she presented with progressive weakness and dyspnea, ultimately found to have a large pleural effusion requiring intervention. This case highlights the challenges in managing TKI-related adverse effects, particularly in elderly patients.

Volume

17

Issue

6

First Page

e85873

DOI

10.7759/cureus.85873

ISSN

2168-8184

PubMed ID

40656327

Link to Full Text

Share

COinS